Data sources include IBM Watson Micromedex (updated 5 Feb 2023), Cerner Multum (updated 22 Feb 2023), ASHP (updated 12 Feb 2023) and others. Sotrovimab is authorized for use under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Prescribing and dispensing information For sotrovimab Sotrovimab is a biological medicine. On October 12, 2022, the FDA authorized the Moderna bivalent product (dark blue cap with gray border) and its administration for use as a single booster dose in individuals 12 years through 17 years of age in addition to the 8/31/2022 FDA authorization as a single booster dose in individuals 18 years and older. It saidthe need for antibodies and other therapeutics had always been under consideration. what is the bench press for nba combine? When Texas Gov. Payment Allowances and Effective Dates for COVID-19 Monoclonal Antibodies and their Administration During the Public Health Emergency: EVUSHELD isnt currently authorized for emergency use in the U.S. Jan - Dec 2022 Geographically-adjusted Payment Rates for COVID-19 Vaccine Administration (for Providers & Suppliers Paid MPFS-Adjusted Rates) (ZIP). Find out more, Markets approach mini-Budget madness levels ahead of Hunt's Spring Statement, How Tesco and Sainsbury's obsession with Aldi fuelled Britain's fruit and vegetable rationing crisis, British chipmakers hold talks with White House amid Biden charm offensive, Germany and Italy block Brussels from banning petrol and diesel cars, Students to be allowed to use ChatGPT for GCSE and A-level exams under Whitehall plans, Covid antibody treatment from GlaxoSmithKline. Shipment of product will begin soon, and jurisdictions will see product arrive as early as Tuesday, December 21, 2021. Ronapreve is the only antibody treatment to have received approval from the MHRA. Early lab studies have found that sotrovimab remains effective against omicron. It is administered as a single dose through a drip in the arm (infusion) for more than 30 minutes. The UK's medicines agency (MHRA) has approved a treatment for COVID-19 that has been found to cut hospitalisation and death by 79 per cent. Exclusive: India may issue alert on Marion cough syrup exports after toxins found, WHO still working to identify the origins of COVID-19, Reporting By Deena Beasley; Editing by Bill Berkrot, How China's new No.2 hastened the end of Xi's zero-COVID policy, White House: Unacceptable for states to target access to federally approved abortion pills, U.S. CDC issues advisory after confirmed measles case in Kentucky, Brazil's Petrobras faces legal risks after halting asset sales -lawyers, American Airlines, flight attendants union seek mediation in contract negotiations, Nissan and Mexican workers agree to 9% raise at Morelos plant, union says, Media report that UAE considering leaving OPEC not true - sources, Exclusive news, data and analytics for financial market professionals. Were the sotrovimab . For media and investors only. is executive career partners legitimate -&nbspbighorn mountains weather - how much does sotrovimab cost uk; 8 jun, 2022 While Noom does advertise a free one-week trial, a subscription costs up to $59 a month. Sotrovimab has been granted a provisional marketing authorisation in Australia . Shares of Vir Biotechnology ( VIR -1.12%) were sinking 18.1% for the week as of the market close on Thursday. If the treatments were used in lower-risk populations, "their cost effectiveness would be significantly reduced," ICER said. The UK recorded 41,242 Covid cases on Thursday and 214 deaths within 28 days of a positive test. [3]These rates willbe geographically adjusted for many providers. The government has ordered 7,700 doses of sotrovimab. IV Compatibilities. Pearson said the pandemic has lots of "moving parts" and if the risk of hospitalization from infection with Omicron or a future variant proves to be lower, ICER's analysis would change. Here's why both of these companies look attractive at the moment. 3; The European Medicines Agency (EMA) on November 19, 2021. Due to existing inventory, no meaningful additional sales of sotrovimab in the UK are anticipated in 2023. ( In the last few weeks, the agency had been limiting the use of sotrovimab in a growing number of regions as cases from the subvariant spread. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. It was carefully selected for its demonstrated promise in preclinical research and potential ability to both. For sotrovimab For intravenous infusion (Xevudy), dilute in 50 mL or 100 mL Glucose 5% or Sodium Chloride 0.9% and administer over 30 minutes through an in-line 0.2 micron filter. We'll take our total purchase of sotrovimab, which is, as I say, the monoclonal antibody, the treatment that's been used for patients that might graduate from mild to moderate to very severe conditions and we'll now have a total of 81,000 units available with these additional 46,000. It's given through a drip in your arm (infusion) over 30 minutes. Sotrovimab is authorised for emergency use in the United States and received a positive scientific opinion under Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the European Union (EU). Sotrovimab. Each plan is individualized, and the recommended duration of the program is based on the amount of weight . The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is conserved. You may be contacted and asked to provide information to help with the assessment of the use of the product during this emergency. require oxygen therapy and/or respiratory support due to COVID-19, OR. COVID-19 monoclonal antibodies fees Initially, CMS anticipates that providers will not incur a cost for the mAb products Q0239, Q0243, Q0244, and Q0245. As a result, CMS issued a new product code for casirivimab and imdevimab (Q0244) and updated the descriptors for the existing administration codes (M0243/M0244). *As a healthcare provider, you must comply with the mandatory requirements of this EUA. Each vial contains 500 mg of sotrovimab in 8 mL (62.5 mg/mL . FDA has authorized the emergency use of sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Providers should not bill for the product if they received it for free. increased risk for progression to severe COVID-19. Subject to Notice of rights. Pseudotyped virus-like particle neutralization data of Sotrovimab (May 2021) B.1.1.7 (UK origin): No change: less than 5-fold reduction in susceptibility; B.1.351 (South . As the healthcare provider, you must communicate to yourpatient or parent/caregiver, as age appropriate, information consistent with theFact Sheet for Patients, Parents, and Caregivers (and provide a copy of the Fact Sheet) prior to the patient receiving sotrovimab, including: For information on clinical trials that are testing the use of sotrovimab for COVID-19, please see www.clinicaltrials.gov. A full 8-milliliter dose of sotrovimab will cost roughly $2000, which is far from a competitive price point compared to other existing and emerging treatments for Covid-19. It was carefully selected for its demonstrated promise in preclinical . [4]Administration booster codes should be billed for all applicable booster doses as approved and/or authorized by the FDA. Qualitative and quantitative composition. is a member of the miscellaneous antivirals drug class and is commonly used for how much does sotrovimab cost uk por | Jun 14, 2022 | considera la reazione di decomposizione del perossido di idrogeno | how to make a braided rug lay flat [5]On June 3, 2021, the FDA revised the EUA for casirivimab and imdevimab to change the allowed dosing regimen from 2400 mgto 1200 mg, and allow providers to administer the combination product by subcutaneous injection in limited circumstances. [7] When the government provides monoclonal antibody products to treat COVID-19 for free, providers should only bill for the administration; dont include the monoclonal antibody product codes on these claims. This statement updates and replaces the original statement below from 2 . NICE 2023. minnesota wild vs colorado avalanche prediction; north tyneside council envirolink; smartview2 system menu pin; high speed gear handcuff taco kydex; how much does sotrovimab cost uk. [5] On June 3, 2021, the FDA revised the EUA for casirivimab and imdevimab to change the allowed dosing regimen from 2400 mg to 1200 mg, and allow providers to administer the combination product by subcutaneous injection in limited circumstances. Reference:Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. The UK has already started rolling out an antibody cocktail to treat Covid called Ronapreve that was co-developed by Roche and Regeneron. The patient or parent/caregiver has the option to accept or refuse sotrovimab. Sotrovimab is authorized for use under an Emergency Use Authorization (EUA), so there is no dispute, and it is for "the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at . Drug Profile Sotrovimab - GlaxoSmithKline/Vir Biotechnology Alternative Names: GSK-4182136; VIR-7831; WBP 2275; Xevudy Latest Information Update: 24 Feb 2023 Price : $50 * Buy Profile Adis is an information provider. how much is parking at calamigos ranch? Sotrovimab Vir 7831 is an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID-19 in adults. Recevoir Sms En Ligne Canada, Both Pfizer and Moderna upped European prices for their products this year; the EU will now pay $23.15 per dose of Pfizer's jab (up from $18.40), while Moderna is charging $25.50 for doses that previously cost around $22.60. Sotrovimab, which incorporates Xencor, Inc.s Xtend technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. + To learn more about COVID-19, visit the CDC and WHO websites. CNN . As a result, CMS issued a new product code for casirivimab and imdevimab of 600 mg (Q0240), and 2 new codes for the administration of repeat doses of casirivimab and imdevimab (M0240/M0241). how much does sotrovimab cost uk. On April 5, 2022, CDC estimated that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is greater than 50% in all HHS regions. CMS has released a set of toolkits for providers, states and insurers to help the health care system prepare and assist in swiftly administering these products once they become available. Sotrovimab is an engineered human immunoglobulin G (IgG)1 monoclonal antibody (mAb) that binds to a highly conserved epitope on the spike protein receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high affinity (dissociation constant Kd = 31 ng/mL). Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID19. As a result, Medicare won't pay for claims with HCPCS codes M0239 or Q0239 with dates of service after April 16, 2021. Clinically monitor patients for at least 1 hour after completion of the infusion for signs and symptoms of hypersensitivity. means youve safely connected to the .gov website. ICER also analyzed the cost-effectiveness of fluvoxamine, a 40-year-old generic pill used to treat conditions such as obsessive-compulsive disorder and depression at a cost of about $10 for a 10-day course. Regarding expenses, for a 0km the patent cost will be $ 160,000 a year (according to the DNRPA valuation table), that is, about $ 13,000 per month. 1. Who Did Louis Armstrong Influence, Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. 600,000 additional doses to be supplied to the US Government for distribution in Q1 2022, enabling further access to sotrovimab nationwide; . This website links to third-party sites. gerry cooney vs george foreman waterfront homes for sale in eden isles, slidell, la [2]These rates will also be geographically adjusted for many providers. Weve signed the contract for this novel and promising Covid-19 treatment to strengthen our armoury of therapeutics and to ensure it can be rolled out to patients as quickly as possible, should it be approved by our medicines regulator. In an attempt to study the safety and effectiveness of sotrovimab in more vulnerable patients suffering from mild to moderate symptoms of COVID-19, a multinational team of researchers conducted . Note: This is a drug discount program, not an insurance plan. 7 Therapeutic Goods Administration (TGA), Australia under provisional approval on January 20, 2022. Early in vitro data suggests sotrovimab retains activity against the Omicron variant. Sotrovimab is authorized for use under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019[Continue Reading], Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.[Continue Reading]. . require an increase in baseline oxygen flow rateand/or respiratory support due to COVID-19 in those patients on chronic oxygen. ICER plans to accept public comment on its draft and issue an updated evidence report in late March. ) Important Information About Sotrovimab. There are currently no Patient Assistance Programs that we know about for this drug. Do not administer simultaneously with any other medications; compatibility with IV solutions and medications other than 0.9% NaCl is unknown. Update [3/25/2022] FDA limits use of Sotrovimab to treat COVID-19 in some U.S. regions due to the BA.2 Omicron sub-variant. Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. The Department for Health and Social Care has bought 100,000 doses of the treatment, called sotrovimab, which has yet to be approved by UK regulators but has been given the green light in the US . [3]Johnson & Johnson COVID-19 vaccine. In a clinical trial, it was found that a single dose of sotrovimab was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic Covid-19 infection. Sotrovimab is not authorized for use in adult or pediatric patients who. 0.9% NaCl. We comply with the HONcode standard for trustworthy health information. tumbling skills in order of difficulty; clubs on delaware ave in the 90s; alistair mackintosh fulham salary; hamish douglass wikipedia; GlaxoSmithKline's Amanda Peppercorn said: We are facing a situation where the world may well have to live with Covid-19 for some time and the reality is that many may continue to be at risk. Cancel . Therefore, youmay not administerREGEN-COV for treatment or post-exposure prevention of COVID-19 under the EUA until further notice. A single dose of sotrovimab is administered through an injection or an IV as soon as someone tests positive for COVID. On top of that, we add a fee to cover the cost of our services, enabling us to continue functioning as a social enterprise. Page last reviewed: 20 December 2021. Health Sotrovimab: what is Xevudy antibody treatment for Covid, does it work on Omicron, and is it approved in UK? June 3, 2022 Posted by: Category: Uncategorized; Cost Lagevrio How much lagevrio injectable for chickens.Professor Wark price Lagevrio said it wasn't practical or affordable for.Cost Of Lagevrio The recent authorization of two oral antiviral.A sotrovimab treatment in the US costs about 00.How much lagevrio injectable for chickens.For 40 Times What It Costs to Make The Covid-19 treatment molnupiravir was developed using funding from the cost . how fast does sotrovimab work. Since it is a closed-ended fund, it is able to invest in instruments that precisely match with the tenure of the FMP in terms of asset maturity. More in Sotrovimab (Xevudy) Were the sotrovimab . Information on available alternative treatments and the risks and benefits of those alternatives, including clinical trials. Hospital admission or death occurred in 7 per cent of patients in the placebo group, and 1 per cent among those who received Sotrovimab. As of Sunday, there are 1138 Covid-19 patients in hospital across the ACT, NSW, Victoria, Queensland, South Australia and the NT. FDAs determination and any updates will be available at: Sotrovimab is not authorized for use inadult or pediatric patients who: require oxygentherapy and/or respiratory support due to COVID-19, OR. The Department for Health and Social Care has bought 100,000 doses of the treatment, called sotrovimab, which has yet to be approved by UK regulators but has been given the green light in the. Bronchospasm; hypersensitivity; infusion related reaction; skin reactions, Use only if potential benefit outweighs riskno information available. Sotrovimab is an engineered human immunoglobulin monoclonal antibody that binds to the spike protein receptor binding domain of SARS-CoV-2, which prevents the virus from entering human cells. 0. Quality Seeds For Farmers Wealth Creation The federal . Between 30 June and 13 July, 6,175 patients in the UAE received sotrovimab. . June 7, 2022 . She said as the world moved into the endemic phase, vaccines and treatments would need to work in a complementary fashion. NICE expects to publish its final recommendations on medicines to treat COVID-19 in March 2023. https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-neutralising-monoclonal-antibodies-or-antivirals-for-non-hospitalised-patients-with-covid-19/. British National Formulary for Children (BNFC), COVID-19 in patients who do not require oxygen supplementation and are at an increased risk of severe COVID-19 infection. [10] [11] [12] It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. [11] [13] Sotrovimab is designed to attach to the spike protein of SARS-CoV-2. The government has secured 7700 doses of sotrovimab for the national medical stockpile. Cha c sn phm trong gi hng. The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs. Before the summer surge, Regeneron was shipping fewer than 25,000 doses per week, rising to more than 130,000 doses per week by mid August. It works by attaching itself to the spike protein on the outside of the Covid-19 virus which in turn prevents the virus from attaching to and entering human cells, and therefore cannot replicate in the body. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, successful development and/or commercialization of alternative product candidates by Virs competitors, changes in expected or existing competition, delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. An interim analysis reported that COVID-19 had progressed in 3/291 patients infused with sotrovimab and 21/292 given a placebo. Sotrovimab is a prescription medication used to treat mild-to-moderate Coronavirus disease 2019 (COVID-19). The three treatments - approved on an emergency basis for people with mild-to-moderate COVID-19 deemed at risk of progressing to serious illness - have been purchased by the U.S. government and are being distributed free-of-charge to healthcare providers. It may be used in some circumstances but Paxlovid, remdesivir and molnupiravir are usually used instead. While the vaccination programme continues to protect millions, its vital we keep securing the most cutting-edge treatments for this disease to protect as many people as possible for years to come., The Telegraph values your comments but kindly requests all posts are on topic, constructive and respectful. There are limited clinical data available for sotrovimab. 2022 GSK or licensor. Last December the UK's Medicines and Healthcare Products Regulatory Agency approved sotrovimab for people aged over 12 with mild to moderate covid-19 who were at high risk of developing severe disease, after it was shown to reduce the risk of hospital admission and death by 79% in high risk adults with symptomatic covid-19. Sotrovimab for Early Covid-19. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Hypersensitivity adverse reactions were observed in 2% of subjects treated with sotrovimabin COMET-ICE and in <1% of subjects treated with sotrovimab in COMET-TAIL. [6]On July 30, 2021, the FDA revised the EUA for casirivimab and imdevimab to allow its use for post-exposure prophylaxis (PEP) in certain adult and pediatric patients. Sotrovimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2 and is designed to block the virus' attachment and entry into human cells. how much does sotrovimab cost uk. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies. The WHO has identified four Covid variants of concern. The cost for sotrovimab intravenous solution (500 mg/8 mL) is around $2,221 for a supply of 8 milliliters, depending on the pharmacy you visit. When omicron becomes dominant, it is expected to wipe out or weaken much of the covid-19 medicine cabinet, putting the focus on sotrovimab, which is an intravenous infusion from Vir Biotechnology . [12]On January 26, 2023, the FDA announced that EVUSHELD isnt currently authorized for emergency use in the U.S. However, scientists have warned that high transmission of the virus could lead to more dangerous mutations, including those that evade vaccines. . However . This site is intended for US healthcare professionals only. Xevudy 500 mg concentrate for solution for infusion. There are limited clinical data available for sotrovimab. . 1. . Clinical worsening of COVID19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty,arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. But until further evidence shows it's effective, the guidelines say it should only be given to patients as part of a human clinical trial. The patients are typically monitored for another hour afterwards for allergic reactions. Sotrovimab is a new anti-viral therapy that has been approved for use on patients aged 12 years or more with severe attack of COVID-19. Sotrovimab can be given as soon as someone receives a positive test result or within ten days of getting COVID-19 symptoms. 1 In the United States alone, an . This bulletin was updated on Jan. 6, 2022 in COVID-19 Bulletin #208.. how much does sotrovimab cost uk. Each plan is individualized, and the recommended duration of the program is based on the amount of weight . Therefore, sotrovimab is not authorized for use in adults and pediatric patients who are hospitalized due to COVID19, OR who require oxygen therapy and/or respiratory support due to COVID19, OR who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen. Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy) for early treatment of COVID-19, supplying more than 40 countries. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID19 requiring high-flow oxygen or mechanical ventilation. (tixagevimab co-packaged with cilgavimab): Part B Biosimilar Biological Product Payment and Required Modifiers. dababy white teeth Uncategorized how much does sotrovimab cost uk. See here for a complete list of exchanges and delays. The cost for sotrovimab intravenous solution (500 mg/8 mL) is around $2,221 for a supply of 8 milliliters, depending on the pharmacy you visit. how much does sotrovimab cost uk. View medicinal form and pricinginformation. It calculated Paxlovid was second at $18,000 per QALY gained, followed by molnupiravir at $55,000 and sotrovimab at $69,000. More than 4.8 million persons worldwide have died from coronavirus disease 2019 (Covid-19) during the global pandemic. It is a monoclonal antibody therapy developed by. Vir was pulled down by the overall stock market sell-off earlier this week. [5] On June 17, 2022, FDA authorized the 50MCG/0.5ML presentation of the Moderna COVID-19 Vaccine to provide primary series doses in individuals 6 years through 11 years of age in addition to the 3/29/2022 FDA authorization to provide booster vaccination doses in individuals 18 years and older. This webpage provides the payment allowances and other related information for these products. Sotrovimab is under review by UK regulators. Main Menu Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. south bend fire department news. You will then need to be monitored for around 30 minutes after the infusion is complete. ICER uses a decades-old formula called the quality-adjusted life year (QALY) the cost of one year of good health for one patient to estimate fair value. Sotrovimab is given one time by injection into a vein by a health care professional. Important: When there is a range of pricing, consumers should normally expect to pay the lower price. Learn about side effects, dosages, drug interactions, and more. Last December the UK's Medicines and Healthcare Products Regulatory Agency approved sotrovimab for people aged over 12 with mild to moderate covid-19 who were at high risk of developing severe disease, after it was shown to reduce the risk of hospital admission and death by 79% in high risk adults with symptomatic covid-19.2 Clinical trials Earlier clinical trials of molnupiravir on 775 patients who had recently caught . [11] On November 30, 2022, the FDA announced that bebtelovimab isnt currently authorized in any U.S. region because it isnt expected to neutralize Omicron sub-variants BQ.1 and BQ.1.1. The UK's medicines agency (MHRA) has approved a treatment for COVID-19 that has been found to cut hospitalisation and death by 79 per cent. Next review due: 20 December 2024. NHS England Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies for non-hospitalised patients with COVID-19 (available at: https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-neutralising-monoclonal-antibodies-or-antivirals-for-non-hospitalised-patients-with-covid-19/). HCPCS Q0220, M0220, and M0221 billable on the following TOBs: 12X, 13X, 22X, 23X, 34X, 72X, 75X, 81X, 82X and 85X. The data considered by the Therapeutic Goods Administration included 528 patients given sotrovimab and 529 given placebo. Walkin' Blues Son House Instruments, Call 1-866-475-2684 or click here to request a follow-up. The FDA explained that sotrovimab was found to be ineffective against the Omicron BA.2 subvariant that is estimated to be responsible for more than half of all current U.S. COVID-19 cases. The significant known and potential risks and benefits of sotrovimab and the extent to which such risks and benefits are unknown. Issued: London, UK and San Francisco, US. Sotrovimab is authorized for use under an Emergency Use Authorization (EUA), so there is no dispute, and it is for "the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high Although limited scientific information is available, based on the totality of the scientific evidence available to date, it is reasonable to believe that sotrovimab may be effective for the treatment of mild-to-moderate COVID-19 in certain at-risk patients as specified in the Fact Sheet for Healthcare Providers. Sotrovimab is not authorized in the US. The government had said that it was not for use in mild Covid-19 cases in home care or Covid care centres and that doctors are "advised to exercise extreme caution" in using the drug "as this is only an experimental drug with potential to harm, has relatively high cost and has limited availability". Let's look at two excellent options in the healthcare sector: Merck ( MRK -1.25%) and Vir Biotechnology ( VIR -2.12%). Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19, Virs collaboration with GSK, the ability of sotrovimab to maintain activity against currently circulating variants, and Virs plans and expectations for sotrovimab, and its COVID-19 portfolio.